Á lódáil...
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
Bevacizumab is a humanized anti-VEGF monoclonal antibody able to produce clinical benefit in advanced non-squamous non-small-cell lung cancer (NSCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
Landes Bioscience
2013
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3813562/ https://ncbi.nlm.nih.gov/pubmed/23760488 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24425 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|